|
2011
|
|
April 2011: TauRx EGM
TauRx EGM was held on the 11 April 2011, at 1000 am at the location below -
The Regent Singapore
1, Cuscaden Road
Singapore 249715
|
|
January 2011: TauRx AGM
TauRx AGM was held on the 13 Jan 2011, at 1830 at the location below -
DBS Auditorium Level 3.
6 Shenton Way
DBS Building Tower ONE
Singapore 068809
|
|
2010
|
|
December 2010: TauRx makes Press Release.
Please
click here to read press release.
|
|
December 2010: TauRx Granted European Composition of Matter
Patent for Lead Compound in Treatment and Prevention of Neurodegenerative Diseases
including Alzheimer's Disease
TauRx Pharmaceuticals Ltd ("TauRx"), a leader in the discovery and development of
drugs and diagnostics that provide new treatment options for Alzheimer's and other
neurodegenerative diseases, announced that it has been granted a European patent
for its lead compound LMTX, a next generation treatment for Alzheimer's and other
neurodegenerative diseases associated with Tau protein mis-folding. Click here to read full article.
|
|
July 2010: TauRx’s recent Rights Issue over-subscribed
TauRx’s recent Rights Issue exercise which closed on 2 July 2010 was over-subscribed
by 3.52%. TauRx would like to thank our shareholders for their encouragement and
strong support. Shareholders will be receiving the new share certificates via registered
mail shortly.
|
|
July 2010: New publication from TauRx
TauRx has a new publication reviewing the role of Tau Aggregation Inhibitor Therapy
in Alzheimer's Disease.
Click here to download PDF.
|
|
June 2010: TauRx Rights Issue closure extends to 2 July 2010
TauRx has launched a Rights Issue on 8 June 2010 which was initially scheduled to
close on 29 June 2010. In view of requests from many shareholders, the duration
of the offering period has been extended to 5.00 pm ( Singapore time ) on 2
July 2010 ( Friday ).
|
|
June 2010: TauRx to Present at Jefferies 2010 Global Life
Sciences Conference.
Prof Claude Wischik, Executive Chairman of TauRx Pharmaceuticals Ltd will provide
a corporate summary and updates on TauRx's clinical program for disease modifying
agents for Alzheimer's disease at the Jefferies Conference. Professor Wischik will
also review the company's recently announced diagnostic collaboration with Bayer
Schering Pharma, the potential of a diagnostic to improve the management of Alzheimer's
disease and also its potential supporting role in disease prevention. The presentation
will be given at the Jefferies 2010 Global Life Sciences Conference in New York
on June 9th, 2010 at 4:30 p.m. Eastern Time.
|
|
May 2010: TauRx enters collaborative R&D agreement with
Bayer Schering Pharma.
WisTa Laboratories Ltd.(a wholly owned subsidiary of TauRx Pharmaceuticals) has
entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany
that could redefine the way Alzheimer?s disease and related disorders are currently
being diagnosed and treated. Through this collaboration, the two companies will
develop specific markers that will aid in the diagnostics and management of Tau-protein
related Alzheimer?s disease using brain imaging technology. The diagnostic they
are jointly aiming to develop will have application in disease treatment and potentially
disease prevention.
Click here
to download a PDF version of the press release.
|
|
April 2010: TauRx enters into agreement with global clinical
research organization INC Research to initiate preparations for Phase 3.
Following the appointment of Dr. Hans Moebius as Chief Medical Officer, TauRx has
undertaken a competitive bid and review process to identify the most suitable partner
to take forward its Phase 3 program. TauRx has now entered into an agreement with
INC Research via a Letter of Intent [forming a broad Alliance] to initiate preparations
for Phase 3 studies in mild and moderate AD, and also in orphan indications such
as Fronto-Temporal Dementia and provisionally Progressive Supranuclear Palsy.
|
|
March 2010: TauRx Group Receives EU Notice of Willingness
to Grant Patent for AD Therapeutics.
TauRx Pharmaceuticals Group Company, WisTa Laboratories Ltd, has been notified by
the European Patent Office that they are willing to grant a patent for a group of
second-generation rember™ derivatives discovered by and under development
at the Company. These compounds have the same mechanism of action as rember™
acting as Tau Aggregation Inhibitors, with potential utility in the treatment of
Alzheimer’s disease and other neurodegenerative disorders. Preclinical and
early clinical studies indicate that one of the compounds which delivers the same
active moiety as rember™ has superior clinical bioavailability and tolerability
profiles than rember™, presenting the potential to achieve relatively higher
dosing levels and enhanced clinical benefit compared to the already striking
clinical effects seen with rember™.
|
|
March 2010: Clinical Trials Initiated Under US IND with Second-Generation
form of rember™.
TauRx is continuing the clinical evaluation of LMTX, a second-generation form of
rember™, that delivers the same active moiety as rember™ into the blood,
in healthy elderly volunteers now under an open US IND. TauRx has prioritized LMTX
ahead of rember™ due to preclinical and early clinical results indicative
of its improved bioavailability and tolerability, possibly allowing for higher dosing
levels and greater clinical efficacy than the striking effects already seen with
rember™. Preparations are underway to commence phase 3 pivotal clinical
evaluation of LMTX during 2010.
|
|
Feb 2010: Interview with TauRx Chairman Prof. Claude Wischik,
Pharmawire.
“TauRx to initiate two global Phase III Alzheimer's trials in 4Q 2010, in
advanced stage of CRO selection and active US investigator discussions” –
Wischik describes the Company’s plans to take forward late stage clinical
development of its second generation Tau Aggregation Inhibitor. More...
|
Jan 2010: Interview with TauRx Chairman Prof. Claude Wischik,
Caledonian Mercury.
“Long journey to lift curse of this awful disease” – Prof. Wischik
describes aspects of the medical and societal impact of Alzheimer’s disease
and the process of developing an AD therapeutic. More...
|
|
2009
|
|
Dec 2009: CMO Appointed, Clinical Management Team Operational.
Dr Hans Moebius has been appointed by TauRx as Chief Medical Officer. Moebius previously
led the clinical development of Memantine, a blockbuster therapeutic for Alzheimer’s
disease, and has deep expertise in the clinical development of various central nervous
system disorders and in clinical operations. The appointment coincided with the
establishment of the company’s senior clinical trial management team and network
of associated clinicians, regulatory affairs experts, statisticians and clinical
trial operations staff.
|
|
Nov 2009: TauRx begins program of clinical evaluation of
LMTX
TauRx begins a program of clinical evaluation of LMTX, a proprietary next generation
form of rember™, with a single ascending dose study and comparison with rember™
in elderly healthy volunteers and files for UK MHRA approval.
|
|
July 2009: ICAD Presentation.
ICAD Presentation (International Conference on Alzheimer’s disease). Prof.
Claude Wischik, TauRx Chairman and Cofounder presented “Issues in Design of
a Phase 3 Disease Modifying Clinical Trial of Tau Aggregation Inhibitor Therapy
in Alzheimer’s disease” at ICAD (International Conference on Alzheimer's
Disease).
|
July 2009: Vienna (and Burkina Faso): What's New With Methylene
Blue?
Wischik provides Alzforum Q&A on Company’s development plans for rember™
and the second generation follow on compound LMTX.
Wischik also responds to erroneous comments made by others regarding the July 2008
ICAD presentation – ie there was no pooling of groups in any of the analyses,
all analyses respected the original randomisation. More...
|
|
May 2009: Pre-IND Meeting, US FDA; Transition from rember™
to Second-Generation Product LMTX. Bridging Studies Initiated.
TauRx met with representatives of the US FDA to clarify the phase 3 clinical trial
strategy for its lead Alzheimer’s disease program and to agree the regulatory
dossier required for LMTX: a proprietary next-generation form of rember™ delivering
the same active moiety that has been prioritised ahead of rember™ due to its
enhanced bioavailability and tolerability. Following the meeting, the Company began
the implementation of a range of supplementary preclinical and clinical studies
to position LMTX as the Company’s lead candidate for evaluation in pivotal
phase 3 clinical trials commencing in 2010.
|
|
Jan 2009: TauRx’s rember™is a top 20 science
story in 2008 at Discover Magazine.
The science focused magazine ranked rember™ phase 2 AD trial results as number
18 of the top 100 most important science stories published by the magazine in 2008.
rember™ shared this position with Medivation’s Dimebon, another
candidate therapeutic for AD that does not share rember™’s mechanism
of action. More...
(Note: A phase 3 evaluation of Dimebon in mild and moderate AD failed to show any
clinical benefit, but trials to compare Dimebon's activity in other patient groups
are ongoing.)
|
|
2008
|
|
August 2008: TauRx Closes US$35M Finance Round.
TauRx secured funds from new and existing investors to support the continued expansion
and development of its pipeline of compounds for the diagnosis and treatment of
Alzheimer’s disease and related disorders.
|
|
July 2008: Consultation with European EMEA.
TauRx met with representatives of the EMEA under the Scientific Advice Procedure
to clarify clinical strategy, regulatory dossier and statistical design requirements
for the further clinical evaluation of rember™ in Alzheimer’s disease.
|
|
July 2008: TauRx Presents rember™ Phase 2 AD Trial
Results at ICAD.
The Company presented the results of its phase 2 rember™ trial in 321 patients
with mild or moderate Alzheimer’s disease at the International Conference
for Alzheimer’s disease. rember™ showed evidence of reducing the rate
of progression of Alzheimer’s disease by 80%, compared to placebo, in this
large, multinational trial.
Links to Press Reports
Business Week: More...
Channel News Asia: More...
Telegraph (UK): More...
USA Today: More...
|
